Actively Recruiting
Long-term Safety and Efficacy Study of HRS-7249 Injection in Adults with Hypertriglyceridemia
Led by Fujian Shengdi Pharmaceutical Co., Ltd. · Updated on 2026-10-09
400
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and effectiveness of HRS-7249, an injection that targets APOC3 to reduce triglyceride levels, in adults with hypertriglyceridemia. This Phase II, multi-center, open-label extension study enrolls two groups participants who recently completed a previous related study and newly recruited patients with elevated fasting triglycerides. The study aims to assess how well repeated doses of HRS-7249 are tolerated and their impact on lipid levels, blood sugar control, pancreatitis, and major heart-related events. Participants receive subcutaneous injections of HRS-7249 in either a low-dose or high-dose regimen for 48 weeks. After completing treatment, they enter a 24-week safety follow-up phase. The study includes two cohorts one of individuals rolling over from a prior trial within 24 weeks, and another of new patients aged 18 to 79 with fasting triglycerides of at least 2.3 mmolL. The treatment is administered according to randomized assignment to one of the two dosing groups. Throughout the study, participants undergo regular safety assessments including vital signs, physical exams, blood tests, ECGs, and monitoring for injection site reactions and other adverse events. Researchers also track changes in lipid profiles, HbA1c, and rates of acute pancreatitis and cardiovascular events over 72 weeks. The study will monitor drug levels in plasma and immune responses to the treatment. Overall participation lasts approximately 72 weeks, covering treatment and follow-up periods.
CONDITIONS
Brief Title
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
Research Team
C
Chanjuan Deng, MM
J
Jianpeng Su, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here